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Nucleotide kinasesTenofovir (TFV), an acyclic nucleoside phosphonate analogue of 2′-
deoxyadenosine, remains a ﬁrst-line choice for the treatment of HIV in-
fections under its prodrug form (i.e. tenofovir disoproxil fumarate, TDF).
During the last decade, the use of TFV in pre-exposure prophylaxis (PrP)
was ﬁrst investigated as a vaginal microbicide gel (Mayer et al., 2006).
More recently, rectal microbicide preparations and oral TDF alone
or in combination with emtricitabine have been evaluated in PrP
(Marrazzo et al., 2015), opening a new era in the ﬁght against HIV.
Clinical studies using TFV-based regimens in PrP provided inconsistent
results, which have been primarily explained by poor adherence.
The study by Lade et al. (2015) explored whether differences in the
mechanism of TFV activation in peripheral blood mononuclear cells
(PBMCs), vaginal and colorectal tissues exist. Also, they examined
whether genetic variation in the nucleotide kinases that activate the
drug could be responsible for the discrepant results observed in PrP
studies using TFV-based regimens.
To be active, TFV requires two successive phosphorylation catalyzed
by cellular kinases. Then, its active diphosphate form (TFV-DP) targets
the HIV reverse transcriptase leading to inhibition of viral replication.
The ﬁrst step of TFV activation is substrate-speciﬁc and requires phos-
phorylation by a cellular adenylate kinase (AK). The isoform AK2 is
known to be localized in the mitochondrial intermembrane space and
to catalyze TFV phosphorylation in a more efﬁcient manner than its
cytoplasmic counterpart AK1.
Lade et al. (2015) found that AK2 activates TFV to TFV-MP in PBMCs
and vaginal and colon tissues from healthy, HIV-uninfected donors thatDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.07.008.
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AK2-dependent activation of TFV. The ﬁrst issue is whether AK2 exists
as a cytosolic form in PBMCs and in vaginal and colorectal tissues.
Several studies reported the existence of small amounts of AK2 in the
cytosol of porcine and rat tissues (Nobumoto et al., 1998; Watanabe
et al., 1979). In contrast, Jurkat cells, a human leukemic T cell line,
showed the absence of AK2 in the cytosol (Kohler et al., 1999). If small
amounts of AK2 are present in the cytosol, will these low AK2 levels
produce sufﬁcient TFV-MP to afford anti-HIV activity? If AK2 is only
expressed in the mitochondrial intermembrane space, then the activa-
tion of TFV will be performed exclusively in the mitochondria. Hence,
the second issue is that TFV activation in the mitochondria will necessi-
tate export of the phosphorylated form (TFV-MP or TFV-DP) into the
cytosol via an active transport in order to exert its anti-HIV activity
and to avoidmitochondrial toxicity. Several reports described TFVmito-
chondrial toxicity in renal proximal tubular cells (Lebrecht et al., 2009),
while others showed no toxicity inHepG2 cells and skeletalmuscle cells
(Birkus et al., 2002). Furthermore, it is known that the use of TFV can be
associated, in some cases, with renal dysfunction and Fanconi syn-
drome. Therefore, it will be interesting to investigate in PBMCs, vaginal
and colorectal tissues the localization of AK2 and the mitochondrial
transporter(s) that might contribute to the export of TFV-MP and/or
TFV-DP.
The second step of TFV activation involves kinases that recognize a
wide range of substrates. Several nucleoside diphosphate kinases
(NDPKs) can be responsible for the production of TFV-DP, including
NDPK1, NDPK2, pyruvate kinase (PK), phosphoglycerate kinase (PGK),
and creatine kinase (CK). Interestingly, the analysis by Lade and col-
leagues points to a role of PK in the conversion of TFV-MP to TFV-DP
in PBMCs and vaginal tissue, while CK appeared to be responsible for
the formation of TFV-DP in colon tissue. Theseﬁndings are in agreement
with enzymatic results reported by Varga et al. showing a CK-mediated
phosphorylation of TFV-MP, without excluding a possible role for PK
(Varga et al., 2013).
In their study, Lade et al. (2015) also highlight the notion that genetic
variants within the nucleotide kinases that exhibit enzymatic activity
towards TFV exist, which may inﬂuence drug pharmacokinetics and
drug efﬁcacy. By means of next-generation targeted sequencing of the
Microbicide Trials Network MTN-001 clinical samples, they identiﬁed
genetic variants in the genes encoding for the kinases involved in TFV
activation. The functional impact of the detected genetic variants was
predicted using in silico tools, therefore, their attempt to correlate the
detected genetic variants to enzyme function is purely predictive.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the participants of the MTN-001 study was low, the authors could not
make strong correlations with published TFV pharmacokinetic data
(Hendrix et al., 2013). Further research should focus on the expression
of recombinant enzymes produced by site-directed mutagenesis in
order to test the impact of the identiﬁed genetic variants on TFV activa-
tion. Also, future studies that would correlate genotype with TFV
pharmacology are also important in order to predict clinical outcomes.
Taken together, the study reported in this issue of E-BioMedicine
(Lade et al., 2015) is an important step in two new concepts. First, the
activation of TFV is tissue speciﬁc due to differential nucleotide kinase
expression and activity which may be linked to potential differential
pharmacology of TDF. Second, genetic variants of the kinases that
activate TFV could impact TFV activation, inﬂuencing the efﬁcacy of
TFV in the prophylaxis and treatment of HIV.
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